

17th  
**ICML**

International  
Conference  
on Malignant  
Lymphoma  
Lugano



GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE



## “State of the Art in Malignant Lymphoma”

ICML-ESMO  
Full-immersion Course

**10-12 June 2023**  
Hotel De La Paix, Lugano (Switzerland)  
*preceding 17-ICML, 13-17 June 2023*

### Structure of the course:


- Plenary lectures
- Case presentations
- Workshops in small groups
- Ample discussion slots

*Maximum number of participants:  
80 (first come-first served basis)*

Detailed information will be soon available  
at [www.icml.ch](http://www.icml.ch)

### Learning objectives:


- Background knowledge of biology and molecular pathology of haematological cancers
- practice-oriented presentation of the modern diagnostic tools
- essential perspective of clinical features of lymphoma entities
- comprehensive overview of the most relevant treatment options, covering also the “unmet needs” and the open questions.



17th  
**ICML**


International  
Conference  
on Malignant  
Lymphoma  
Lugano

June  
13-17  
2023



## Preliminary Program

[@icmlugano](https://twitter.com/icmlugano)  
[#17ICML](https://twitter.com/17ICML)



Organized by



In cooperation with



American Association  
for Cancer Research™

FINDING CURES TOGETHER™



GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

## KEY DEADLINES

### Registration and deadlines

On-site participation (including online access):

• Early registration	February 28, 2023*	CHF 1000
• Regular registration	March 01 – May 31, 2023*	CHF 1200
• Late registration	from June 01, 2023*	CHF 1400

**\* Due to space restrictions, attendance is limited. On-site registrations will close prior to the deadlines if the maximum number of participants is reached.**

Virtual participation:

• Early registration	February 28, 2023	CHF 700
• Late registration	from March 01, 2023	CHF 900

### Discounted registration fees:

Participants living in low and lower-middle income countries

• Virtual participation	CHF 350
-------------------------	---------

Nurse practitioners (NEW)

• On-site participation (including online access)	CHF 500
• Virtual participation	CHF 350

### Abstract submission deadlines

Abstracts can be related to all aspects of biology and treatment of lymphoid neoplasms, including CLL and multiple myeloma.

• Regular submission	March 15, 2023
• Late-Breaking Abstracts submission	May 25, 2023**

**\*\* By the regular abstract deadline, a covering letter must be sent to [abstract@icml.ch](mailto:abstract@icml.ch), indicating the data expected to be available by the Late-Breaking abstract deadline.**

### Hotel booking

**Amiconi Consulting SA ([info@amiconiconsulting.ch](mailto:info@amiconiconsulting.ch)) is the 17-ICML official housing agent.**

Due to heavy room demand, **early booking is advisable.**

All efforts will be made to assign hotel rooms according to the participants' choice. However, should this not be possible, alternative category and/or location will be provided.

Please visit [www.icml.ch](http://www.icml.ch) for more information.

Printed by courtesy of



## PROVISIONAL SCIENTIFIC PROGRAM

Updated on May 30, 2022

Based on the abstracts received and accepted for oral presentation, general sessions will be devoted to either specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc), or to the presentation of laboratory and clinical research data grouped around a biologic topic (e.g. microenvironment, signalling pathway, surface antigens).

The program will also include two sessions devoted entirely to basic and translational research topics ("Dissecting lymphomas at the single cell level" and "Epigenetic mechanisms and targeted therapies in B- and T-cell lymphomas"). Abstracts related to these topics will be evaluated for presentation during these two sessions.

### Key Note Lectures:

#### • Henry Kaplan Memorial Lecture and San Salvatore Foundation Award

Genetic and Microenvironmental Features of Large B-cell Lymphomas

Margaret A. Shipp, Boston, MA (United States)

#### • Gianni Bonadonna Memorial Lecture - supported by ESO (European School of Oncology)

Elucidating the enigmatic pathobiology of Hodgkin lymphoma

Ralf Küppers, Essen (Germany)

#### • John Ultmann Memorial Lecture - supported by AACR (American Association for Cancer Research)

25 years of antibody treatments for lymphoma

Peter W.M. Johnson, Southampton (United Kingdom)

### Educational symposia (parallel sessions):

#### DLBCL

• CAR T-cells: Gilles Salles, New York, NY (United States)

• Bispecific antibodies: Martin Hutchings, Copenhagen (Denmark)

• New agents: Ranjana H. Advani, Stanford, CA (United States)

#### CLL

• Biology: Nicholas Chiorazzi, Manhasset, NY (United States)

• First line therapy: Michael Hallek, Cologne (Germany)

• Therapy of relapsed disease and Richter's Syndrome: John F. Seymour, Melbourne (Australia)

### Meet the Professor sessions:

• Advances in PET and radiomics: Sally Barrington, London (United Kingdom)

• Cutaneous T-cell lymphomas - some problems and some solutions: Helmut Beltraminelli, Locarno (Switzerland)

• CNS lymphoma (primary and secondary) treatment and prophylaxis: Kate Cwynarski, London (United Kingdom)

• Mantle Cell: Martin Dreyling, Munich (Germany)

• Update on Follicular Lymphomas: Jonathan W. Friedberg, Rochester, NY (United States)

• Post-transplantation lymphoproliferative disorders in children and adolescents: Thomas Gross, Aurora, CO (USA)

• Peripheral T-cell lymphomas: Steven M. Horwitz, New York, NY (United States)

• Are we reaching the maximum cure rate for Hodgkin lymphoma?: Peter W.M. Johnson, London (United Kingdom)

• Germinal center in the genesis of lymphomas: Laura Pasqualucci, New York, NY (United States)

• Lymphoma in pregnancy: Fedro A. Peccatori, Milan (Italy)

• Reappraisal of role of RT in lymphoma treatment: Lena Specht, Copenhagen (Denmark)

• Marginal zone lymphomas: Emanuele Zucca, Bellinzona (Switzerland)